Glide Pharma has raised a further GBP2.2m to develop the Glide SDI - Solid Dose Injector.
The Glide SDI is now in feasibility studies for delivering vaccines and biopharmaceuticals with five partners.
Through a one-click action, the pen-like device of the Glide SDI pushes the solid dose, in the form of a tiny, pointed rod, through the skin where it subsequently dissolves to release the drug or vaccine to the body.
In patient acceptance trials, participants have expressed a preference for the Glide SDI system over a traditional needle and syringe injection.
Dr Charles Potter, Glide Pharma's chief executive officer, said: 'This funding reflects the major progress we have made in positioning the Glide SDI system as a mainstream alternative for the injection of small molecules, biopharmaceuticals and vaccines.
'With five external funded studies underway in addition to our internal drug development programmes for octreotide and fentanyl, we feel confident in moving forward.
'Preliminary data from these studies, together with a vaccine feasibility study with the UK's National Institute of Biological Standards and Control (NIBSC), is already very encouraging.'
